Anupam Rasayan buys Bliss GVS Pharma for ₹2,200 cr
Anupam Rasayan is paying ₹299 per share to take control of Bliss GVS Pharma, pivoting from specialty chemicals into finished dosage manufacturing.
— 2 earlier stories on Anupam Rasayan India Ltd. →What's new
- Anupam Rasayan is buying a 43.30% stake in Bliss GVS for ₹1,369.51 cr.
- A mandatory open offer for an additional 26% stake is set at ₹299 per share.
- The deal adds finished dosage manufacturing to Anupam Rasayan's specialty chemicals business.
Why this matters
This acquisition changes the company's business model by moving it into finished dosage manufacturing. At 15.5% of Anupam Rasayan's market capitalization, the deal is a material capital allocation that requires immediate model revisions.
What we're watching
- The completion of the mandatory open offer process.
- Integration timelines for the new finished dosage manufacturing segment.
- How the company funds the ₹2,200 cr cash outlay.
The full read
Anupam Rasayan is moving into the pharmaceutical sector. The board approved the acquisition of up to 74.20% of Bliss GVS Pharma for a total consideration of approximately ₹2,198.54 crore. The deal structure includes a 43.30% stake purchase at ₹299 per share, costing ₹1,369.51 crore, followed by a mandatory open offer for another 26% at the same price, valued at ₹829.03 crore. Bliss GVS, which posted a turnover of ₹1,001 crore last year, brings niche manufacturing capabilities in suppositories and tablets to Anupam Rasayan’s existing specialty chemicals portfolio. At 15.5% of Anupam Rasayan’s ₹14,172 crore market capitalization, this is a material change in strategy. The company is betting its balance sheet on a new vertical, moving from chemical intermediates into finished dosage manufacturing. The next test is the execution of the open offer and the integration of these two distinct business models.
Questions answered
- What is the total cost of the acquisition?
- The total consideration is approximately ₹2,198.54 crore, covering the initial 43.30% stake and the 26% open offer, with room for an additional 4.90% stake.
- What does Bliss GVS Pharma do?
- Bliss GVS manufactures niche pharmaceutical products, including suppositories and tablets, and reported a turnover of ₹1,001 crore in the last financial year.
- What is the price per share for the acquisition?
- Both the initial share purchase and the mandatory open offer are priced at ₹299 per share.
- How large is this deal relative to Anupam Rasayan?
- The total consideration of ₹2,200 crore is about 15.5% of Anupam Rasayan's market capitalization of ₹14,172 crore.
Story so far
All notes on ANURAS →- Today · 7:39 PM IST Anupam Rasayan buys Bliss GVS Pharma for ₹2,200 cr
- 1d ago Anupam Rasayan revenue jumps 65% in FY26 as margins slip to 23%
- 1d ago Anupam Rasayan buys 74.20% of Bliss GVS Pharma